Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1501-1520 of 1,738 trials

Midgut Neuroendocrine Tumors: Lu177-Dotatate Treatment Schedule

We are studying whether giving Lu177-Dotatate every 16 weeks can lower serious side effects for patients with advanced midgut neuroendocrine tumors. This trial compares the new schedule to the standard treatment given every 8 weeks.

Small Intestine Neuroendocrine Tumor>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyOncology

Small Cell Lung Cancer: MK-6070 and Ifinatamab Deruxtecan Study

We are studying the safety and effectiveness of MK-6070 combined with ifinatamab deruxtecan in people with advanced small cell lung cancer. This trial aims to find better treatment options for those whose cancer has returned or is hard to treat.

Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Septic Shock: Comparing Sodium Lactate and Saline Solutions

We are studying how two different intravenous fluids affect blood flow and acid-base balance in patients with septic shock. This research may help improve treatment options for this serious condition.

Septic Shock>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicinePulmonology

Autoimmune Uveitis: Probiotic Supplement Study

We are studying the effects of a probiotic on people with autoimmune uveitis to see if it improves vision and reduces inflammation. The trial will also check the safety of this treatment.

Autoimmune Uveitis1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesOphthalmology

Blood Cancer Treatment: SMART101 After Stem Cell Transplant

We are studying the safety and effectiveness of SMART101 for patients with blood cancers after stem cell transplantation. The goal is to see if it helps improve immune recovery and reduce complications.

Allogenic Stem Cell Transplantation>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyInfectious Diseases

Alzheimer’s Disease: NTRX-07 Treatment Study

We are investigating the safety and tolerability of NTRX-07 in people with mild cognitive impairment or mild to moderate Alzheimer's disease. This study aims to understand how well the treatment works and its effects on patients.

Mild Cognitive Impairment (MCI)Mild to Moderate Alzheimer's Disease (AD)≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesNeurology

Leukemia Treatment: Ponatinib vs. Imatinib

We are studying whether ponatinib combined with chemotherapy is as effective as imatinib for adults with Philadelphia-Chromosome positive acute lymphoblastic leukemia. The trial also evaluates treatment outcomes for patients who respond differently.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Cardiac Amyloidosis: PET Imaging with Vizamyl®

We are studying a new imaging tracer to see how effectively it detects amyloid deposits in the hearts of patients with cardiac amyloidosis. This research may help improve diagnosis and understanding of the disease.

Cardiac Amyloidosis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiology

Essential Tremor: BP1.4979 Treatment Study

We are testing a new medication, BP1.4979, for adults with essential tremor to see if it helps reduce symptoms and improve quality of life. The study will also check how safe the treatment is for patients.

Essential Tremor1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Premature Ejaculation: BP1.4979 Study

We are testing a new medication for adult men with primary premature ejaculation to see if it improves ejaculatory control and sexual satisfaction compared to a placebo.

Premature Ejaculation3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatryUrology

Metastatic Breast Cancer: Targeted Treatment Based on Genetic Analysis

We are studying whether targeted therapies guided by genetic testing can improve survival for patients with metastatic breast cancer compared to standard chemotherapy. This trial aims to personalize treatment based on individual genetic profiles.

Metastatic Breast CancerEfficacy phase (II)No PlaceboStandard MedicinesOncology

Oxytocin and Trust Learning in Attachment Development

We are exploring how oxytocin may influence trust learning and cognitive flexibility in a virtual reality setting. This study aims to understand its effects on social bonding and learning processes.

Healthy Children>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsStandard MedicinesPsychiatry

Colorectal Cancer: Telisotuzumab Adizutecan Treatment

We are studying a new treatment for adults with colorectal cancer who have positive circulating tumor DNA but no visible disease. The goal is to see if this treatment improves disease-free survival compared to standard care.

Colorectal Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

HER2-Positive Cancer: Trastuzumab Deruxtecan Study

We are exploring a new treatment for HER2-positive cancer using a blood test to monitor changes in HER2 status. This study aims to improve treatment personalization and assess the safety of the new medication.

Metastatic HER2-Positive Breast CancerEfficacy phase (II)No PlaceboStandard MedicinesOncology

Septic Shock: Mesenchymal Stem Cells Treatment

We are studying whether early administration of mesenchymal stem cells can improve organ function in patients with septic shock. This trial compares the effects of MSCs to standard treatment in intensive care.

Severe Septic Shock>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyInfectious DiseasesInternal MedicinePulmonology

Ozone Therapy for Chemotherapy-Induced Pain Relief

We are studying whether adding ozone therapy helps cancer patients with painful neuropathy feel better and improve their quality of life. This trial will also look at the costs and safety of this treatment.

Chemotherapy-Induced Peripheral Neuropathy3-6 monthsEfficacy phase (II)Confirmation phase (III)Standard MedicinesNeurologyOncology

Prostate Cancer: Ebastine with Docetaxel or Cabazitaxel

We are studying a new treatment combining ebastine with either docetaxel or cabazitaxel for men with metastatic castration-resistant prostate cancer. The goal is to evaluate how this combination affects cancer markers and PSA levels.

Hormone-Refractory Prostate Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Penile and Tongue Cancer: New Imaging Technique

We are evaluating a new fluorescent imaging method to help surgeons visualize tumors and lymph node spread during surgery for penile and tongue cancer. This study aims to improve detection and assess any side effects.

Penile CancerTongue Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyUrology

Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder

We are studying whether a high dose of psilocybin can help reduce heavy drinking in people with severe alcohol use disorder during inpatient rehabilitation. This trial also examines the safety and effects on mental health and cognitive function.

Severe Alcohol Use Disorder6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementInfectious DiseasesPsychiatry

Acute Myeloid Leukemia: Eganelisib Treatment Study

We are studying the safety and tolerability of eganelisib alone and with cytarabine in patients with relapsed or refractory acute myeloid leukemia. This trial aims to find the best dose and evaluate how well the treatment works.

Relapsed/Refractory Acute Myeloid LeukemiaHigher-Risk Myelodysplastic SyndromesSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology